Literature DB >> 20127140

Photodynamic therapy for choroidal neovascularization in young adult patients.

Rita Ehrlich1, Michal Kramer, Irit Rosenblatt, Dov Weinberger, Karin Mimouni, Ethan Priel, Ruth Axer-Siegel.   

Abstract

We report our experience with photodynamic therapy (PDT) in the treatment of choroidal neovascularization (CNV) in young adult patients. This was a retrospective study of young adults with CNV treated with PDT. Data collected included age, diagnosis, type and size of CNV, number of treatments, visual outcome, and side effects. Ten patients (11 eyes) were included in the study (mean age 27.2 +/- 13.3 years). Etiologies included multifocal choroiditis (3 eyes), idiopathic CNV (5 eyes), central serous chorioretinopathy (1 eye), and toxoplasma (2 eye). The mean number of treatments was 2 +/- 0.7 and the mean follow-up time was 13.1 +/- 9.5 months. Initial visual acuity (VA) ranged from 20/25 to 20/1,200 (mean logMAR 0.6 +/- 0.5), and improved to 20/20 to 20/250 (mean logMAR 0.46 +/- 0.4) (P = 0.51). Of the four eyes that received additional treatment with oral steroids, one of which also received intravitreal bevacizumab (Avastin) injections, all had visual acuity improvement of 2 or more lines, while only two of seven eyes that received PDT alone showed such improvement. PDT can improve visual outcome in a subgroup of young patients with subfoveal CNV especially when supplemented with oral steroid and bevacizumab injections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127140     DOI: 10.1007/s10792-010-9346-3

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  34 in total

1.  Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.

Authors:  Kevin J Blinder; Mark S Blumenkranz; Neil M Bressler; Susan B Bressler; Guy Donato; Hilel Lewis; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi M Mones; Michael J Potter; Constantin Pournaras; Al Reaves; Philip Rosenfeld; Andrew P Schachat; Ursula Schmidt-Erfurth; Michel Sickenberg; Lawrence J Singerman; Jason S Slakter; H Andrew Strong; Gianni Virgili; George A Williams
Journal:  Ophthalmology       Date:  2003-04       Impact factor: 12.079

2.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

3.  Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series.

Authors:  Andrew C Browning; A K K Chung; F Ghanchi; S P Harding; M Musadiq; S J Talks; Y C Yang; W M Amoaku
Journal:  Ophthalmology       Date:  2005-07       Impact factor: 12.079

4.  Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females.

Authors:  Laurence Postelmans; Brigitte Pasteels; Pascale Coquelet; Hind El Ouardighi; Claire Verougstraete; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2004-11       Impact factor: 5.258

5.  Photodynamic therapy in young patients.

Authors:  Andrew Lam; Henry C Lee; Allen C Ho; Carl D Regillo; J Arch McNamara; Mitchell D Fineman
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2006 May-Jun

6.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

7.  Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization.

Authors:  Subrata Mandal; Satpal Garg; Pradeep Venkatesh; Charu Mithal; Rajpal Vohra; Abhas Mehrotra
Journal:  Arch Ophthalmol       Date:  2007-11

8.  Concentric retinal pigment epithelium atrophy after a single photodynamic therapy.

Authors:  Joachim Wachtlin; Tim Behme; Heinrich Heimann; Ulrich Kellner; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-05-07       Impact factor: 3.117

9.  Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults.

Authors:  Adam H Rogers; Jay S Duker; Neil Nichols; Brad J Baker
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

10.  Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.

Authors:  Ursula Schlötzer-Schrehardt; Arne Viestenz; Gottfried O H Naumann; Horst Laqua; S Michels; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-27       Impact factor: 3.117

View more
  2 in total

1.  Intravitreal bevacizumab as a primary treatment for idiopathic choroidal neovascularization.

Authors:  Rizwan A Cheema; Javed Mushtaq; Maheera A Cheema
Journal:  Middle East Afr J Ophthalmol       Date:  2011-07

Review 2.  Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy.

Authors:  Enzo D'Ambrosio; Paolo Tortorella; Ludovico Iannetti
Journal:  J Ophthalmol       Date:  2014-04-27       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.